ArticleFrontiers in oncology2023

Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study.

Bo Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.